The study demonstrated the significant benefit of using certolizumab pegol in addition to nonbiologic background medications in patients with nonradiographic axial spondyloarthritis exhibiting objective signs of inflammation.
There is a pressing need to identify barriers to optimizing ankylosing spondylitis therapy within the treatment guidelines.
Study identifies several disease-specific factors associated with the risk of mental disorders in patients with axial spondyloarthritis.
The VIBE technique identified articular destructive damage in patients with axial spondyloarthritis.
Inflammatory bowel disease occurs with an incidence of 1/100 patient-years in early spondyloarthritis.
Findings support the interchangeable use of the terms radiographic axial spondyloarthritis and ankylosing spondylitis.
The use of age- and height-adjusted reference intervals could significantly improve spinal mobility assessment during the course of ankylosing spondylitis disease.
Improvements to the traditional Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) were necessary to meet the requirements of Rasch Measurement Theory resulting in the identification of a modified 5-item BASDAI measure that demonstrated good precision and internal validity.
Investigators assessed the incidence of hearing loss among patients with ankylosing spondylitis and its relationship to nonsteroidal anti-inflammatory drug intake.
Investigators compared clinical impression and confidence of extended role practitioners with that of rheumatologists experienced in axial spondyloarthritis.